Plant-derived products to prevent metabolic diseases. Pipeline incl 5+ products targeting prediabetes/T2D, NAFL/NASH, dyslipidaemia, and obesity. Lead program VALEDIA®, targets unaddressed prediabetes market. Ph 2a in prediabetics for reduction of risk factors for developing T2; results 2019. VALEDIA® demonstrated good tolerance in Ph 1/2 trial in healthy volunteers; during meal test, improvement of glucose tolerance (-13% Glucose Cmax), reduction in insulin secretion (-37% Insulin AUCnet), and improvement of insulin sensitivity (41%).
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Valbiotis NDR SF/Boston/NY Feb 2019
February 12 –
February 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by